Anthony T C Chan Selected Research

Carcinoma (Carcinomatosis)

08/2008	Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
07/2008	CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
07/2008	Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients.
06/2008	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
04/2008	Proteomic Comparison of Nasopharyngeal Cancer Cell Lines C666-1 and NP69 Identifies Down-Regulation of Annexin II and beta(2)-Tubulin for Nasopharyngeal Carcinoma.
01/2008	A novel application of plasma and cerebrospinal fluid level of epstein barr virus DNA in the diagnosis of leptomeningeal metastasis from nasopharyngeal carcinoma. A case report.
11/2007	Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.
04/2007	Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor.
12/2006	Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma.
12/2006	Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
11/2006	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
09/2006	Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.
04/2006	Reduced plasma RNA integrity in nasopharyngeal carcinoma patients.
01/2006	Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients.
01/2006	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma.
11/2005	Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma.
08/2005	Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine.
05/2005	Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
04/2005	Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.
01/2005	Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma.
12/2004	Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
10/2004	Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma.
08/2004	Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
08/2004	Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
03/2004	Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas.
02/2004	Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
10/2003	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
08/2003	Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.
07/2003	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
05/2003	Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients.
11/2002	Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
10/2002	A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
08/2002	Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.

Articles by Research Topic

Disease

33	Carcinoma (Carcinomatosis) 08/2008 - 08/2002
9	Hepatocellular Carcinoma (Hepatoma) 08/2008 - 07/2002
8	Neoplasms (Cancer) 08/2008 - 10/2003
3	Small Cell Carcinoma 04/2008 - 01/2005
2	Colorectal Neoplasms (Colorectal Cancer) 01/2008 - 11/2007
2	Neoplasm Metastasis (Metastasis) 01/2008 - 12/2006
2	Anoxia (Hypoxia) 04/2007 - 08/2002
2	Lymphoma (Lymphomas) 10/2004 - 05/2003
2	Hepatitis B 08/2004 - 03/2004
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 04/2008
1	Laryngeal Neoplasms (Laryngeal Cancer) 03/2008
1	Liver Neoplasms (Liver Cancer) 01/2004
1	Pleural Effusion (Pleural Effusions) 05/2003
1	Breast Neoplasms (Breast Cancer) 07/2002

Drug/Important Bio-Agent (IBA)

17	DNA (Deoxyribonucleic Acid)IBA 08/2008 - 11/2002
4	Cisplatin (Platino)FDA LinkGeneric 09/2007 - 08/2004
4	alpha-Fetoproteins (AFP)IBA 11/2005 - 07/2002
2	AntigensIBA 07/2008 - 03/2004
2	gemcitabine FDA Link 04/2008 - 01/2005
2	docetaxel (Taxotere)FDA Link 09/2007 - 07/2002
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2007 - 08/2002
2	cetuximab (Erbitux)FDA Link 12/2006 - 05/2005
2	Lamivudine (3TC)FDA Link 08/2005 - 03/2004
2	Carboplatin (JM8)FDA LinkGeneric 05/2005 - 08/2004
2	Etoposide (VP 16)FDA LinkGeneric 01/2005 - 10/2002
1	UbiquitinIBA 08/2008
1	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 04/2008
1	Annexin A2 (Annexin II)IBA 04/2008
1	Oncogene Proteins (Oncogene Protein)IBA 03/2008
1	Iodized Oil (Lipiodol)IBA 01/2008
1	Ethanol (Ethyl Alcohol)IBA 01/2008
1	beta CateninIBA 01/2008
1	Messenger RNA (mRNA)IBA 11/2007
1	irinotecan (Camptosar)FDA LinkGeneric 09/2007
1	olsalazine (Dipentum)FDA Link 07/2007
1	GTPase-Activating Proteins (GTPase-Activating Protein)IBA 07/2007
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2007
1	HaptoglobinsIBA 10/2006
1	RNA (Ribonucleic Acid)IBA 04/2006
1	epothilone B (EPO906)IBA 01/2006
1	beta-galactosideIBA 11/2005
1	Ferritins (Ferritin)IBA 08/2004
1	antigen CYFRA21.1IBA 08/2004
1	Paclitaxel (Taxol)FDA LinkGeneric 08/2004
1	Azacitidine (5 Azacytidine)FDA Link 04/2004
1	Immunoglobulin A (IgA)IBA 02/2004
1	Epstein-Barr viral capsid antigenIBA 02/2004
1	OGT 719IBA 01/2004
1	Epidermal Growth Factor Receptor (EGF Receptor)IBA 10/2003
1	Topotecan (Hycamtin)FDA Link 10/2002
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 08/2002
1	Epirubicin (Ellence)FDA LinkGeneric 07/2002

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 04/2008 - 03/2004
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 11/2007 - 12/2004
1	Immunotherapy 04/2008